GlassScriptPhysician profile
Arturo A Bravo
NPI 1952372484
$16,666.41
in general payments reported to CMS, 2019-2025
33 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,773 · 2020: $1,073 · 2021: $1,399 · 2022: $2,977 · 2023: $1,215 · 2024: $3,845 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,222 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,580 · Travel and Lodging: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,580.00 |
| Travel and Lodging | $641.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,449.40 | 2019-2025 | Linzess, Viberzi |
| Allergan, INC. | $2,895.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $2,787.15 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,664.04 | 2019-2025 | Xifaxan |
| Braintree Laboratories, INC. | $1,102.39 | 2019-2025 | Sutab, Suflave |
| Medtronic, INC. | $1,004.58 | 2021-2025 | Gi Genius, Pillcam |
| Gilead Sciences, INC. | $807.39 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $493.88 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $400.96 | 2019-2025 | Eohilia |
| Intercept Pharmaceuticals, INC. | $375.81 | 2019-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $209.29 | 2025 | Iqirvo |
| Janssen Biotech, INC. | $207.54 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $191.23 | 2023-2025 | Ibsrela |
| Intra-Sana Laboratories | $158.25 | 2021 | |
| Ironwood Pharmaceuticals, INC | $149.14 | 2019-2024 | Linzess |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $100.24 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $92.60 | 2021-2023 | Talicia |
| Intuitive Surgical, INC. | $92.21 | 2023 | Da Vinci Surgical System |
| Ethicon US, LLC | $61.78 | 2020 | |
| Qol Medical, LLC | $53.14 | 2019-2021 | |
| Pfizer INC. | $50.39 | 2022-2024 | |
| Concordia Pharmaceuticals INC. | $45.56 | 2019 | |
| Evoke Pharma, INC. | $41.96 | 2023-2024 | Gimoti |
| Endo Pharmaceuticals INC. | $39.50 | 2019 | |
| Covidien LP | $37.81 | 2020 | |
| Ferring Pharmaceuticals INC. | $37.36 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $28.96 | 2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $21.74 | 2024 | Dificid |
| Azurity Pharmaceuticals, INC. | $18.09 | 2025 | Sutab |
| Capsovision, INC. | $17.54 | 2025 | Capsocam Plus |
| Emmaus Medical, INC. | $13.32 | 2019 | |
| Boston Scientific Corporation | $12.40 | 2020 | |
| Perspectum Diagnostics LTD | $5.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Bravo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.